Shepherd F A
Department of Medicine, Toronto Hospital, Ontario, Canada.
Semin Oncol. 1994 Jun;21(3 Suppl 4):48-62.
Lung cancer is now the leading cause of cancer-related mortality for both men and women in North America. Non-small cell lung cancer (NSCLC) accounts for 75% to 80% of all primary lung tumors. Although the survival rate for patients with NSCLC remains poor, recent advances in our knowledge of the pathophysiology and biology of lung cancer have paved the way for the development of new, more effective therapeutic interventions. This paper reviews the current status and future prospects for the management of NSCLC, including adjuvant therapy following surgical resection for stages I, II, and IIIA disease; induction chemotherapy for locally advanced stages IIIA and IIIB disease; chemotherapy for advanced stage IV disease; and biologic response modifiers, including interferons, interleukins, colony-stimulating factors, and monoclonal antibodies.
肺癌目前是北美男性和女性癌症相关死亡的主要原因。非小细胞肺癌（NSCLC）占所有原发性肺肿瘤的75%至80%。尽管NSCLC患者的生存率仍然很低，但我们对肺癌病理生理学和生物学认识的最新进展为开发新的、更有效的治疗干预措施铺平了道路。本文综述了NSCLC治疗的现状和未来前景，包括I、II和IIIA期疾病手术切除后的辅助治疗；局部晚期IIIA和IIIB期疾病的诱导化疗；晚期IV期疾病的化疗；以及生物反应调节剂，包括干扰素、白细胞介素、集落刺激因子和单克隆抗体。
